-
Electronic (PDF)
-
Site License
-
Enterprisewide
Thalidomide - Analysis and Market Forecasts from 2015 to 2020
GlobalData, July 2011, Pages: 27
Thalidomide – Analysis and Market Forecasts from 2015 to 2020
Summary
GlobalData’s pharmaceuticals report, “Thalidomide – Analysis and Market Forecasts from 2015 to 2020” provides Thalidomide sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US and EU5
- Analysis and review of Thalidomide including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Thalidomide including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2015-2020 for Thalidomide in the US and EU5
-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Liver Cancer Market
2.2 Epidemiology
2.3 Etiology
2.3.1 Hepatitis B Infection
2.3.2 Hepatitis C Infection
2.3.3 Alcohol
2.3.4 Aflatoxin B1
2.3.5 Hemochromatosis
2.3.6 Diabetes and Obesity
2.3.7 Cirrhosis
2.4 GlobalData Report Guidance
3 Liver Cancer : Market Characterization
3.1 Liver Cancer Market
3.2 Liver Cancer Market Forecasts and CAGR
3.3 Drivers for the Liver Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality
3.3.3 Large Unmet Need
4 Tumor–Node–Metastases (TNM) Classification of Liver Cancer
5 Thalidomide
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of Thalidomide
5.4.1 TACE – Gold Standard Treatment
5.4.2 Teratogenicity
5.5 Drug Risk Benefit Score
5.5.1 Relative Efficacy
5.5.2 Safety
5.5.3 Compliance
5.5.4 Dosing Convenience
5.6 Intensity of Competition
5.7 Sales Forecasts
5.7.1 Target Patient Pool of Thalidomide
5.7.2 Dosing
5.7.3 Market Penetration
5.7.4 Annual Cost of Therapy
5.7.5 Sales Projections of Thalidomide
6 Liver Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.3.8 Primary Research
6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
1.1 List of Tables
Table 1: Liver Cancer, Incidences and Mortality, 2008–2030
Table 2: Drug Risk Benefit Score (DRB)
Table 3: Thalidomide, Liver Cancer, Global, Estimated Sales ($m), 2015–2020
Table 4: Thalidomide, Liver Cancer, The US, Estimated Sales ($m), 2015–2020
Table 5: Thalidomide, Liver Cancer, The UK, Estimated Sales ($m), 2016–2020
Table 6: Thalidomide, Liver Cancer, France, Estimated Sales ($m), 2016–2020
Table 7: Thalidomide, Liver Cancer, Germany, Estimated Sales ($m), 2016–2020
Table 8: Thalidomide, Liver Cancer, Italy, Estimated Sales ($m), 2016–2020
Table 9: Thalidomide, Liver Cancer, Spain, Estimated Sales ($m), 2016–2020
1.2 List of Figures
Figure 1: Fatality = [(% Distribution of Incidence) – (% Distribution of Mortality)] of Most Common Cancers
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010–2020
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008–2030
Figure 4: Oncology, Worldwide, Incidence (in millions), 2008–2030
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008–2030
Figure 6: Classification of Liver Cancer
Figure 7: Clinical Trials Results, Thalidomide
Figure 8: Drug Model Diagram of Thalidomide
Figure 9: Thalidomide, Liver Cancer, Global, Estimated Sales ($m), 2015–2020
Figure 10: Thalidomide, Liver Cancer, The US, Estimated Sales ($m), 2015–2020
Figure 11: Thalidomide, Liver Cancer, The UK, Estimated Sales ($m), 2016–2020
Figure 12: Thalidomide, Liver Cancer, France, Estimated Sales ($m), 2016–2020
Figure 13: Thalidomide, Liver Cancer, Germany, Estimated Sales ($m), 2016–2020
Figure 14: Thalidomide, Liver Cancer, Italy, Estimated Sales ($m), 2016–2020
Figure 15: Thalidomide, Liver Cancer, Spain, Estimated Sales ($m), 2016–2020
Figure 16: Thalidomide, Liver Cancer, Global, Sales Distribution (%), 2020
Figure 17: Drug Model Diagram
Figure 18: Patients Approved for the Drug
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
